FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

OAC 4729:5-8-01 defines a nonresident terminal distributor as any person outside Ohio that ships, mails or delivers dangerous drugs at retail into Ohio and requires it to hold a license under ORC 4729.54 and 4729.55; OAC 4729:5-8-03 applies Ohio record-keeping, labeling, counseling-offer, OARRS reporting and delivery rules to drugs sent into Ohio. A nonresident pharmacy that ships compounded drugs into Ohio must name an Ohio-licensed pharmacist as the responsible person on its license (OAC 4729:5-8-04). At initial licensure and every renewal, a compounding nonresident pharmacy must submit an inspection report under 2 years old showing compliance with OAC 4729:5-8-04 (home-state or other regulator, NABP Verified Pharmacy Program, or ACHC Inspection Services), or proof of PCAB, Joint Commission or Compliance Team compounding accreditation. Licensees that sell drugs on a website must use NABP digital pharmacy accreditation (OAC 4729:5-3-08); the Ohio Board of Pharmacy may inspect licensees without notice.

The Board's Feb. 18, 2026 non-resident compounding guidance covers the revised OAC 4729:7-1-01 (newest USP 797/795, rule effective 2/28/2026, enforcement delayed by Board resolution to 2/28/2027) and restates the Ohio-licensed responsible-pharmacist and inspection-report rules. It does not contain peptide-specific rules. A pharmacy marketing site's claim that the Board issued Feb. 2026 guidance on out-of-state pharmacies shipping compounded peptides could not be matched to any document on pharmacy.ohio.gov. The Board's guidance-document list (checked 2026-09-23) shows GLP-1 guidance (7/17/2025), an FDA letter on retatrutide, and the two compounding guides, but no separate peptide guidance.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

OAC 4729:7-2-03 (effective 3/7/2024) requires a drug compounded in an Ohio pharmacy to be compounded and dispensed under a patient-specific prescription; only a limited quantity may be made ahead of orders, based on regular prescribing patterns. OAC 4729:5-8-04 bars a nonresident pharmacy from selling, shipping, mailing or delivering compounded drugs into Ohio except under a patient-specific prescription. The only exception is non-patient-specific compounded drugs for animal (veterinary office) use; OAC 4729:7-2-05 covers veterinary office use for in-state pharmacies. A pharmacy's 'occasional wholesale sale' to other licensees is defined for commercially manufactured drugs only. Ohio's rule matches FDA's view that 503A compounding must be patient-specific; human office stock would come from a licensed outsourcing facility.

OAC 4729:5-8-04 has been effective since 7/1/2021, so the rule text is more than 2 years old, but the Board restated it in its Feb. 2026 non-resident compounding guidance. Ohio prescribers may compound in their own offices under separate prescriber-compounding rules (OAC Chapter 4729:7-3); that is not office-use supply from a pharmacy. Ohio GLP-1 guidance (7/17/2025) says compounded semaglutide and tirzepatide copies are no longer permitted, that retatrutide and cagrilintide cannot be compounded, and that in-state compounders must buy API from Ohio-licensed distributors.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

ORC 4729.52 requires the Board to license outsourcing facilities, along with manufacturers, wholesalers, third-party logistics providers and repackagers, whether located inside or outside Ohio. A nonresident applicant may qualify with a current outsourcing facility license from a home state with comparable requirements, or with verification by an entity the Board recognizes. OAC Chapter 4729:6-10 sets the operating rules (cGMP under 21 CFR Part 211, security, storage, recalls). An outsourcing facility that sells or dispenses patient-specific drugs must also hold a terminal distributor of dangerous drugs license (OAC 4729:6-10-01).

ORC 4729.52 was most recently amended by HB 96 (136th GA), effective 9/30/2025. The Board's 7/17/2025 GLP-1 guidance says outsourcing facilities must follow cGMP and OAC 4729:6-10, and that compounding of semaglutide and tirzepatide copies ended for outsourcing facilities on 5/22/2025 and 3/19/2025. The Board also posts 'Licensure as an Outsourcing Facility' and 'Ohio Licensed Outsourcing Facilities' documents at https://pharmacy.ohio.gov/pubs/Special; these were not reviewed in detail.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Ohio is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

ORC 4729.541(A) exempts prescribers practicing as sole proprietors and prescriber-owned entities from TDDD licensure, but 4729.541(C)(2) requires even exempt prescribers and practices to hold a TDDD license to possess, have custody or control of, and distribute any Schedule I-V controlled substance (and 4729.541(C)(1) does the same for compounded drugs). The Board's guidance says this applies to any location storing controlled substances, including emergency packs and samples, and that 'distribution' includes on-site administration and personally furnishing; administering only patient-supplied drugs is not distribution. The license is location-specific; ORC 4729.54 sets a $160 fee for in-state prescribers licensed because of 4729.541(C), with the license period set by Board rule (up to 24 months). Prescribing only (no CS kept on site) needs no TDDD; pain management clinics need a category III TDDD even with no drugs on site.

ORC 4729.541 was most recently amended by HB 462 (136th GA), effective 2026-08-26; ORC 4729.54 amended by HB 96 / SB 152 (136th GA), effective 2026-03-04. The Board guidance PDF is dated 2023-08-24 (older than 2 years - check for updates). The TDDD requirement applies equally to NP/PA-owned or -staffed practices that keep CS; NPs/PAs also need prescriptive authority from their own boards. The Board stopped licensing clinics for office-based opioid treatment per its 7/11/2023 resolution.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Medical Board rule OAC 4731-11-11(C)(1) requires a physician to obtain and review an OARRS report before prescribing or personally furnishing an opioid analgesic or benzodiazepine (then every 90 days if treatment lasts over 90 days). Under (C)(2) and (E)(2), when a course of treatment with any other 'reported drug' (all Schedule II-V controlled substances plus other drugs listed by the Pharmacy Board) has lasted more than 90 days, the physician must review OARRS and then at least annually until treatment ends; red flags in (C)(3) also require a check. The duty covers physicians who personally furnish (dispense) drugs. Exceptions in (G) include hospice/terminal illness, drugs prescribed for administration in a hospital, nursing home or residential care facility, supplies of 7 days or less, cancer, and acute pain after surgery, another invasive procedure or delivery.

Source older than 2 years - possibly stale; however, this is the version currently published on the official Ohio code site (accessed 2026-09-23) and its five-year review date is 9/30/2026, so an amendment may be pending. For testosterone the first mandatory OARRS check falls when treatment has lasted more than 90 days (not before the first prescription), then annually. PDMP TTAC also lists nursing (OAC 4723-9-12) and physician assistant (OAC 4730-4-03) rules, which were not opened and may differ.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

ORC 4729.29 lets prescribers personally furnish drugs to their patients within scope, subject to 4729.291. Under 4729.291 a prescriber may not furnish more than a 72-hour supply of a controlled substance to a patient in any 72-hour period, or more than 2,500 dosage units of controlled substances to all patients in 30 days (MAT drugs excepted). Prescribers are exempt from the terminal distributor of dangerous drugs (TDDD) license under 4729.541 unless they possess controlled substances (Schedules I-V), compounded dangerous drugs, or run a pain management clinic. Testosterone dispensing is therefore limited to 72 hours and needs a TDDD license.

4729.541 shows an August 26, 2026 effective version. Compounded dangerous drugs (e.g. compounded GLP-1s) held in the office also trigger TDDD licensure.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) A physician must hold an Ohio license; narrow exemptions include consultation with an Ohio licensee and follow-up care for the same condition within one year after the physician treated the patient in another state (ORC 4731.36(A)(4)). (2) The Medical Board's telehealth rule sets the same standard of care as in-person care; an initial in-person physical exam is required only before prescribing a Schedule II controlled substance to a new patient, with exceptions for hospice/palliative care, MAT/OUD, mental health conditions, emergencies (no more than a 3-day supply) and prescribing under a federal-law exception, and the exception used must be documented. (3) Schedule III-V drugs such as testosterone have no Ohio-specific telehealth limit beyond complying with federal controlled-substance law and OAC 4731-37-01; ORC 4743.09 only lets boards require an in-person visit for Schedule II. (4) IMLC: member.

OAC 4731-11-09 effective 2023-02-28 (five-year review 2028). ORC 4743.09 effective 2025-04-09 (SB 95). Physicians must also comply with federal DEA telemedicine rules, which the Ohio rule incorporates.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The May 2025 joint regulatory statement of the State Medical Board of Ohio, Board of Pharmacy and Board of Nursing states that only a physician, PA or APRN has statutory authority to diagnose a patient's condition and make the decision to provide medication, by injection or otherwise, and that a nominal "medical director" who never sees the patient does not create a valid practitioner-patient relationship. A licensed person other than the prescriber may administer only if it is within their scope, and physicians, PAs and APRNs may not delegate administration of injectable drugs to unlicensed individuals except as specific laws allow (R.C. 4731.053, 4730.203, 4723.489). No Ohio rule specific to botulinum toxin or fillers was located.

The joint statement is written about IV clinics; applying its prescriber-evaluation requirement to cosmetic injectables is an inference from its general statements about medication given by injection. Check with the Ohio Board of Nursing for injectables-specific guidance.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Under the May 2025 joint statement, a physician, PA or APRN must personally evaluate and diagnose the patient, keep a record, obtain informed consent and issue a prescription before any IV is given; the relationship may be established by telehealth under R.C. 4743.09. Protocols or standing orders for recommending, compounding or administering IV medications are not authorized in retail IV clinics (OAC 4729:5-3-12 lists the only permitted uses). Nurses and paramedics may not diagnose or recommend IVs; an LPN is not authorized to administer IV solutions at a retail IV clinic (LPNs may give only certain plain IV fluids when directed under R.C. 4723.18, and may not start solutions containing vitamins or electrolytes); EMTs may not give IVs; unlicensed staff may not administer IV drugs. Mixing IV cocktails is compounding, requiring a terminal distributor of dangerous drugs licence, and a prescriber must verify a nurse-compounded product or be on site.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Ohio as 'Uncertain (Evolving)', citing R.C. 4731.41(A), Ohio Attorney General Opinion No. 87-049 and 1994 statutory amendments. MedPath Compliance (reviewed 2026-06-20) similarly calls it nuanced and evolving. Med spa operators commonly still use physician-owned entities for medical services, but no clear statutory bar on lay ownership was confirmed.

Statute and AG opinion text not fetched.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

R.C. 4731.33 allows delegation of light-based hair removal to PAs, RNs/LPNs and laser hair removal professionals (former cosmetic therapists or people with 750+ hours of training who pass an exam). The physician must evaluate the patient before the first treatment and again before continuing, delegates need documented training, on-site supervision is required initially (some off-site supervision later for established patients), and one physician may supervise at most five delegates. Under OAC 4731-18 a physician may not delegate ablative procedures; non-ablative vascular laser work may go only to PAs or nurses who complete 8 hours of education, observe 15 and perform 20 supervised procedures, with the physician on site, evaluating the patient first and supervising no more than two delegates at once.

R.C. 4731.33 shows an effective date of 2026-08-26 on the codes site, so it was recently amended; the specific changes were not compared.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Ohio was not among them, but this research did not confirm its statutes. Ohio's CLIA state agency is Ohio Dept. of Health CLIA Laboratory Program (CLIA@odh.ohio.gov, 614-466-1451); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Ohio's rule. Ohio's lab regulator (CLIA state agency) is Ohio Dept. of Health CLIA Laboratory Program (CLIA@odh.ohio.gov, 614-466-1451). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Ohio is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Ohio does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.